Men with erectile dysfunction (ED) should be screened for cardiovascular risk factors – Cost-benefit considerations in Swiss men
Abstract
Summary:Background: Current evidence indicates that erectile dysfunction (ED) is an independent risk factor for future cardiovascular events. This study aimed to estimate the cost-effectiveness of screening and subsequent preventive treatment for cardiovascular risk factors among men newly diagnosed with ED from the Swiss healthcare system perspective. Methods: Based on known data on ED and cardiovascular disease (CVD) prevalence and incidence costs and effects of a screening intervention for cardiovascular risk including corresponding cardiovascular prevention in men with ED were calculated for the Swiss population over a period of 10 years. Results: Screening and cardiovascular prevention over a period of 10 years in Swiss men with ED of all seriousness degrees, moderate and severe ED only, or severe ED only can probably avoid 41,564, 35,627, or 21,206 acute CVD events, respectively. Number needed to screen (NNS) to prevent one acute CVD event is 30, 23, and 10, respectively. Costs for the screening intervention are expected to be covered at the seventh, the fifth, and the first year, respectively. Conclusion: Screening and intervention for cardiovascular risk factors in men suffering from ED is a cost-effective tool not only to strengthen prevention and early detection of cardiovascular diseases but also to avoid future cardiovascular events.
References
1 Federal Administration. Cause of death statistics 2020. In: (BFS) BfS, editor. https://www.bfs.admin.ch/bfs/de/home/aktuell/neue-veroeffentlichungen.assetdetail.23284854.html, 2021
2 . A Swiss National Strategy for 2017–2024. Eur Heart J. 2017;38:3117–8.
3 Productivity loss and indirect costs in the year following acute coronary events in Switzerland. Cardiovasc Med. 2021;24.
4 . Costs associated with cardiovascular disease create a significant burden for society and they seem to be globally underestimated. Eur J Prev Cardiol. 2019;26:1147–9.
5 . How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts. Eur J Health Econ. 2018;19:1149–61.
6 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–337.
7 Heart failure risk associated with severity of modifiable heart failure risk factors: the ARIC study. J Am Heart Assoc. 2022;11:e021583.
8 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.
9 Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388:761–75.
10 Risk for heart failure: the opportunity for prevention with the American Heart Association’s Life’s Simple 7. JACC Heart Fail. 2019;7:637–47.
11 . Ideal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United States. Circulation. 2012;125:987–95.
12 Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012;307:1273–83.
13 . Epidemiology of erectile dysfunction: results of the “Cologne Male Survey”. Int J Impot Res. 2000;12:305–11.
14 . Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460–3.
15 Primary organic versus primary psychogenic erectile dysfunction: findings from a real-life cross-sectional study. Andrology. 2022;10:1302–9.
16 . The etiology of erectile dysfunction and contributing factors in different age groups in Turkey. Int J Urol. 2004;11:525–9.
17 . Erectile dysfunction in men under 40: etiology and treatment choice. Int J Impot Res. 1993;5:97–103.
18 . Erectile dysfunction under age 40: etiology and role of contributing factors. Sci World J. 2004;4(Suppl 1):171–4.
19 Erectile dysfunction as an independent predictor of future cardiovascular events: the multi-ethnic study of atherosclerosis. Circulation. 2018;138:540–2.
20 . Impotence and its medical and psychosocial correlates: results of the massachusetts male aging study. J Urol. 1994;151:54–61.
21 Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. 2003;44:360–4.; discussion 364–5.
22 Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1–25.
23 Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19:133–43.
24 Estimating long-term health utility scores and expenditures for cardiovascular disease from the medical expenditure panel survey. Circ Cardiovasc Qual Outcomes. 2021;14:e006769.
25 . Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. Swiss Med Wkly. 2013;143:w13851.
26 . Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. Swiss Med Wkly. 2013;143:w13732.
27 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.
28 . Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses. BJU Int. 2021;128:3–11.
29 . Erectile dysfunction predicts cardiovascular events as an independent risk factor: a systematic review and meta-analysis. J Sex Med. 2019;16:1005–17.
30 The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87:766–78.
31 Erectile dysfunction: AUA guideline. J Urol. 2018;200:633–41.
32 Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003.
33 Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. Am Heart J. 2012;164:21–8.
34 . Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens. 2004;17(2):139–45.
35 . New insights into hypertension-associated erectile dysfunction. Curr Opin Nephrol Hypertens. 2012;21:163–70.
36 Comparison of the prevalence of erectile dysfunction between hypertensive and normotensive participants: a case-control study. Cureus. 2020;12:e12061.
37 . Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med. 2008;5:2125–34.
38 . Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology. 2004;64:1196–201.
39 Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care. 2002;25:284–91.
40 Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care. 2003;26:1093–9.
41
Shindel AW ,Lue TF . Sexual dysfunction in diabetes. In:Feingold KR ,Anawalt B ,Blackman MR ,Boyce A ,Chrousos G ,Corpas E , et al. Endotext. South Dartmouth (MA): South Dartmouth (MA): MDText.com, Inc. 2000.42 . Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol. 2004;43:1405–11.
43 . Dyslipidemia as a risk factor for erectile dysfunction. Curr Med Chem. 2007;14:1765–70.
44 . Do cigarette smokers with erectile dysfunction benefit from stopping? A prospective study. BJU Int. 2004;94:1310–3.
45 . Is the relationship between cigarette smoking and male erectile dysfunction independent of cardiovascular disease? Findings from a population-based cross-sectional study. J Sex Med. 2009;6:222–31.
46 . Smoking and risk of erectile dysfunction: systematic review of observational studies with meta-analysis. PLoS One. 2013;8:e60443.
47 . The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011;171:1797–803.
48 . Physical activity and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res. 2007;19:245–52.
49 Primary organic versus primary psychogenic erectile dysfunction: Findings from a real-life cross-sectional study. Andrology. 2022;10(7):1302–9.
50 Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. J Sex Med. 2010;7:192–202.
51 A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84:108–13.
52 . Do patients consult their GP for sexual concerns? A cross sectional explorative study. Scand J Prim Health Care. 2017;35:373–8.
53 . The Cardiac Health and Assessment of Relationship Management and Sexuality study: a qualitative inquiry of patient, general practitioner, and cardiac rehabilitation staff views on sexual assessment and counseling for cardiac patients. J Cardiovasc Nurs. 2013;28:E1–13.
54 Endovascular therapy for erectile dysfunction: current knowledge and future perspectives. Minerva Cardiol Angiol. 2021;69:579–595.
55 Erectile dysfunction as a marker for cardiovascular disease diagnosis and intervention: a cost analysis. J Sex Med. 2015;12:975–84.
